Wall Street brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report $44.40 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $43.80 million and the highest estimate coming in at $45.00 million. Vanda Pharmaceuticals posted sales of $38.48 million during the same quarter last year, which would indicate a positive year over year growth rate of 15.4%. The firm is expected to issue its next quarterly earnings results after the market closes on Tuesday, November 7th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $44.40 million for the current year, with estimates ranging from $168.70 million to $172.00 million. For the next financial year, analysts forecast that the business will post sales of $205.70 million per share, with estimates ranging from $194.00 million to $217.40 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The business had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business’s revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.01 earnings per share.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, August 8th. BidaskClub cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $23.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. set a $21.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $21.29.

Vanda Pharmaceuticals (NASDAQ VNDA) opened at 14.70 on Monday. Vanda Pharmaceuticals has a 12 month low of $12.70 and a 12 month high of $18.99. The firm’s market capitalization is $659.41 million. The stock’s 50 day moving average price is $17.08 and its 200 day moving average price is $15.77.

COPYRIGHT VIOLATION NOTICE: “$44.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/30/44-40-million-in-sales-expected-for-vanda-pharmaceuticals-inc-vnda-this-quarter.html.

A number of hedge funds have recently made changes to their positions in the business. Fox Run Management L.L.C. bought a new position in Vanda Pharmaceuticals in the third quarter valued at approximately $696,000. Dynamic Technology Lab Private Ltd boosted its stake in Vanda Pharmaceuticals by 46.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock valued at $335,000 after acquiring an additional 6,487 shares during the last quarter. California State Teachers Retirement System boosted its stake in Vanda Pharmaceuticals by 8.2% in the second quarter. California State Teachers Retirement System now owns 78,040 shares of the biopharmaceutical company’s stock valued at $1,272,000 after acquiring an additional 5,900 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Vanda Pharmaceuticals by 20.3% in the second quarter. The Manufacturers Life Insurance Company now owns 34,882 shares of the biopharmaceutical company’s stock valued at $568,000 after acquiring an additional 5,875 shares during the last quarter. Finally, State Street Corp boosted its stake in Vanda Pharmaceuticals by 2.9% in the second quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock valued at $26,380,000 after acquiring an additional 46,299 shares during the last quarter. 86.45% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.